Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy.
Gianluca IngrossoB DettiA FodorS CainiS BorghesiL TriggianiF TrippaD RussoA BruniG FrancoliniA LanciaL MarinelliN Di MuzioL LiviS M MagriniE MaranzanoD MusioC AristeiM ValerianiPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2021)
Our results suggest that SBRT in oligoprogressive mCPRC is safe, effective and seems to prolong the efficacy of the ongoing systemic treatment positively affecting disease progression. Prospective trials are needed.